阿立哌唑治疗老年期精神分裂症的研究  

Aripiprazole in the Treatment of Senile Schizophrenia

作　　者：张保利[1] 宋亚军[1] 李相桦[1] 兰志敏[1] 冯锋[1] 

机构地区：[1]北京回龙观医院老年科,北京100096

出　　处：《中国医院用药评价与分析》2011年第3期260-262,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨阿立哌唑与利培酮对老年期精神分裂症的疗效和安全性。方法:将86例老年期精神分裂症患者随机分为2组,分别选用阿立哌唑或利培酮治疗,疗程12周,疗效评定采用阳性与阴性症状量表(PANSS)及不良反应量表(TESS)评定疗效和不良反应。结果:治疗12周后2组PANSS评分较治疗前均显著下降。阿立哌唑组有效率69.76%,显效率88.37%;利培酮组有效率72.09%,显效率90.70%,2组间差异无显著性(P>0.05)。结论:阿立哌唑与利培酮治疗老年期精神分裂症均有肯定疗效,不良反应均比较轻,安全性好。OBJECTIVE：To evaluate the efficacy and safety of aripiprazole versus risperdal in the treatment of senile schizophrenia.METHODS：86 patients with senile schizophrenia were randomly assigned to receive either aripiprazole or risperdal for 12 weeks.The positive and negative symptom scale（PANSS） was used to evaluate the curative efficacy and treatment emergent symptom scale（TESS） was used to evaluate the side effects.RESULTS：After treatment of 12 weeks,PANSS scores in both groups decreased significantly as compared before treatment.There were no significant differences between aripiprazole group and risperdal group in effective rate（69.76% vs.72.09%） and obvious effective rate（88.37% vs.90.70%）（P 0.05）.CONCLUSION：Both aripiprazole and risperdal are effective and safe（with mild adverse reactions） for senile schizophrenia.

关 键 词：阿立哌唑 利培酮 老年期精神分裂症 不良反应量表 

分 类 号：R971.41[医药卫生—药品]